Condition 1: Chronic kidney disease, stage 5. Condition 2: dialysis complications. Condition 3: Dialysis-induced inflammation. Condition 4: Hyperlipidemia. Condition 5: hyperglycemia. Condition 6: carnitine deficiency. Condition 7: Disorder of fatty-acid metabolism. Chronic kidney disease, stage 5 Kidney dialysis as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure Infection and inflammatory reaction due to ot
Conditions
Interventions
Intervention 1: Intervention group: Intervention group will receive daily 50 mg per kg of body weight l-carnitine supplement for 8 weeks. L-carnitine syrups will be purchased from the Alborz daru Co
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: at least 2 times a week dialysis three months pass after dialysis at least plasma carnitine to carnitine free ratio greater than 0.4 (indicating a lack of carnitine) desiring to participate in this study
Exclusion criteria
Exclusion criteria: pregnanacy use of non-steroidal and steroidal anti-inflammatory, lipid lowering and beta-blocker medications autoimmune diseases, infectious, inflammatory disease, cardiovascular disease, thyroid disorders, thrombocytopenia nutritional support (enteral and parenteral nutrition)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin-6. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;High sensitivity c-reactive protein. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Immunoturbidimetry.;Total cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic.;Serum tryglycerides. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic.;Low density lipoprotein cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic.;High density lipoprotein cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic.;Serum glucose. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic.;Apolipoprotein A. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic.;Serum carnitine. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assy.;Serum albumin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: questionnare (PedsQL).;Nutritional status (calorie and nutrients intake). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Food record questionnaire.;Anthropometric index(weight, height,WHR and Body Mass Index). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Analogue scale for weight, height, WHR and CDC chart.;Acyl carnitine. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: spectrometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Hossein Imani
Tehran University of Medical Sciences
Outcome results
None listed